175 related articles for article (PubMed ID: 22645448)
21. 1H-MRS evaluation of breast lesions by using total choline signal-to-noise ratio as an indicator of malignancy: a meta-analysis.
Wang X; Wang XJ; Song HS; Chen LH
Med Oncol; 2015 May; 32(5):160. PubMed ID: 25895597
[TBL] [Abstract][Full Text] [Related]
22. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature.
Begley JK; Redpath TW; Bolan PJ; Gilbert FJ
Breast Cancer Res; 2012 Apr; 14(2):207. PubMed ID: 22515594
[TBL] [Abstract][Full Text] [Related]
23. In vivo proton magnetic resonance spectroscopy of breast lesions: an update.
Tse GM; Yeung DK; King AD; Cheung HS; Yang WT
Breast Cancer Res Treat; 2007 Sep; 104(3):249-55. PubMed ID: 17051424
[TBL] [Abstract][Full Text] [Related]
24. Detection of breast malignancy: diagnostic MR protocol for improved specificity.
Huang W; Fisher PR; Dulaimy K; Tudorica LA; O'Hea B; Button TM
Radiology; 2004 Aug; 232(2):585-91. PubMed ID: 15205478
[TBL] [Abstract][Full Text] [Related]
25. ¹H-magnetic resonance spectroscopy of the breast at 3.0-T: comparison of results obtained before and after administration of gadolinium-based contrast agent.
Kawai H; Naganawa S; Satake H; Ishigaki S; Sakurai Y; Mori M; Maruyama K
J Magn Reson Imaging; 2012 Mar; 35(3):717-22. PubMed ID: 22095613
[TBL] [Abstract][Full Text] [Related]
26. The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging.
Dorrius MD; Pijnappel RM; van der Weide Jansen MC; Jansen L; Kappert P; Oudkerk M; Sijens PE
Eur Radiol; 2012 Apr; 22(4):915-22. PubMed ID: 22076317
[TBL] [Abstract][Full Text] [Related]
27. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy.
Bartella L; Thakur SB; Morris EA; Dershaw DD; Huang W; Chough E; Cruz MC; Liberman L
Radiology; 2007 Oct; 245(1):80-7. PubMed ID: 17885182
[TBL] [Abstract][Full Text] [Related]
28. In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.
Bathen TF; Heldahl MG; Sitter B; Vettukattil R; Bofin A; Lundgren S; Gribbestad IS
MAGMA; 2011 Dec; 24(6):347-57. PubMed ID: 21909791
[TBL] [Abstract][Full Text] [Related]
29. MR imaging and proton spectroscopy of the breast: how to select the images useful to convey the diagnostic message.
Fausto A; Magaldi A; Babaei Paskeh B; Menicagli L; Lupo EN; Sardanelli F
Radiol Med; 2007 Oct; 112(7):1060-8. PubMed ID: 17952685
[TBL] [Abstract][Full Text] [Related]
30. High-field MR spectroscopy in the multiparametric MRI evaluation of breast lesions.
Cavedon C; Meliadò G; Rossi L; Camera L; Baglio I; Caumo F; Montemezzi S
Phys Med; 2016 Dec; 32(12):1707-1711. PubMed ID: 27637861
[TBL] [Abstract][Full Text] [Related]
31. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
Sardanelli F; Fausto A; Di Leo G; de Nijs R; Vorbuchner M; Podo F
AJR Am J Roentgenol; 2009 Jun; 192(6):1608-17. PubMed ID: 19457825
[TBL] [Abstract][Full Text] [Related]
32. The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors.
Doganay S; Altinok T; Alkan A; Kahraman B; Karakas HM
Eur J Radiol; 2011 Aug; 79(2):e33-7. PubMed ID: 21376496
[TBL] [Abstract][Full Text] [Related]
33. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T.
Stanwell P; Gluch L; Clark D; Tomanek B; Baker L; Giuffrè B; Lean C; Malycha P; Mountford C
Eur Radiol; 2005 May; 15(5):1037-43. PubMed ID: 15351906
[TBL] [Abstract][Full Text] [Related]
34. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of MR spectroscopy for characterizing malignant breast lesions using a clinical 3-T scanner.
Baek HM; Lee YJ
Breast Cancer; 2015 Sep; 22(5):510-9. PubMed ID: 24390858
[TBL] [Abstract][Full Text] [Related]
36. In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy.
Russo F; Mazzetti S; Grignani G; De Rosa G; Aglietta M; Anselmetti GC; Stasi M; Regge D
Eur Radiol; 2012 May; 22(5):1131-9. PubMed ID: 22138734
[TBL] [Abstract][Full Text] [Related]
37. MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.
Geraghty PR; van den Bosch MA; Spielman DM; Hunjan S; Birdwell RL; Fong KJ; Stables LA; Zakhour M; Herfkens RJ; Ikeda DM
Breast J; 2008; 14(6):574-80. PubMed ID: 19000051
[TBL] [Abstract][Full Text] [Related]
38. Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: an MRI and in vivo proton MRS study.
Sah RG; Sharma U; Parshad R; Seenu V; Mathur SR; Jagannathan NR
Magn Reson Med; 2012 Oct; 68(4):1039-47. PubMed ID: 22213087
[TBL] [Abstract][Full Text] [Related]
39. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.
Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R
Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926
[TBL] [Abstract][Full Text] [Related]
40. Correlation between Choline Peak at MR Spectroscopy and Calcium-Sensing Receptor Expression Level in Breast Cancer: A Preliminary Clinical Study.
Baio G; Rescinito G; Rosa F; Pace D; Boccardo S; Basso L; Salvi S; Calabrese M; Truini M; Neumaier CE
Mol Imaging Biol; 2015 Aug; 17(4):548-56. PubMed ID: 25613673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
